31st Annual J.P. Morgan Healthcare Conference
Keryx: Zerenex Data Held Hostage by Hurricane Sandy
By Marie Powers
Thursday, January 10, 2013
Ron Bentsur, CEO of Keryx Biopharmaceuticals Inc., disappointed some attendees on the final morning of the J.P. Morgan Healthcare Conference when he acknowledged the company is still waiting for Phase III data on Zerenex (ferric citrate) in end-stage renal disease patients with hyperphosphatemia.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.